Home » Stocks » VXRT

Vaxart, Inc. (VXRT)

Stock Price: $6.43 USD -0.70 (-9.76%)
Updated November 24, 12:33 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 703.34M
Revenue (ttm) 7.61M
Net Income (ttm) -24.77M
Shares Out 109.47M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE 40.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $6.43
Previous Close $7.12
Change ($) -0.70
Change (%) -9.76%
Day's Open 6.85
Day's Range 6.20 - 6.94
Day's Volume 7,611,051
52-Week Range 0.27 - 17.49

More Stats

Market Cap 703.34M
Enterprise Value 572.63M
Earnings Date (est) Feb 10, 2021
Ex-Dividend Date n/a
Shares Outstanding 109.47M
Float 108.43M
EPS (basic) -0.12
EPS (diluted) -0.34
FCF / Share -0.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 32.35M
Short Ratio 3.44
Short % of Float 29.84%
Beta 0.12
PE Ratio n/a
Forward PE 40.00
P/FCF Ratio n/a
PS Ratio 92.47
PB Ratio 5.32
Revenue 7.61M
Operating Income -22.44M
Net Income -24.77M
Free Cash Flow -17.11M
Net Cash 130.71M
Net Cash / Share 1.19
Gross Margin -61.50%
Operating Margin -294.96%
Profit Margin -325.60%
FCF Margin -224.90%
ROA -11.63%
ROE -32.90%
ROIC 1,246.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$17.67*
(175.02% upside)
Low
16.0
Current: $6.43
High
20.0
Target: 17.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.864.165.849.3024.6068.7033.6020.4012.5035.01
Revenue Growth137.12%-28.77%-37.22%-62.2%-64.19%104.46%64.71%63.2%-64.29%-
Gross Profit9.864.165.849.3021.0017.6013.9010.5010.0031.05
Operating Income-15.79-21.76-10.02-25.00-26.00-10.10-24.00-23.00-30.50-1.20
Net Income-18.65-18.01-9.58-25.40-19.10-11.00-8.90-19.20-25.400.88
Shares Outstanding21.576.320.143.513.212.852.572.062.050.67
Earnings Per Share-0.86-2.90-91.65-7.26-5.94-3.85-3.52-9.35-12.321.32
Operating Cash Flow-13.09-14.55-10.04-14.10-9.60-3.30-13.90-15.90-33.7039.93
Capital Expenditures-0.85-0.71-0.05-0.200.30-0.10-1.00-1.30-0.70-0.10
Free Cash Flow-13.94-15.26-10.09-14.30-9.30-3.40-14.90-17.20-34.4039.83
Cash & Equivalents13.5311.512.9969.0057.6081.7066.8053.80102108
Total Debt2.313.6140.250.701.00-----
Net Cash / Debt11.217.90-37.2668.3056.6081.7066.8053.80102108
Assets37.0335.234.5272.7079.4011485.8069.30105114
Liabilities24.0823.9943.2526.509.9027.1017.8010.0045.6453.30
Book Value12.9511.24-38.7246.2069.5086.9068.0059.3059.7060.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vaxart, Inc.
Country United States
Employees 30
CEO Andrei Floroiu

Stock Information

Ticker Symbol VXRT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VXRT

Description

Vaxart, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.